Healthcare charges in patients who transition from ocular hypertension to primary open-angle glaucoma based on ophthalmic coding data

被引：0

作者：

Louis R. Pasquale

John G. Walt

Lee S. Stern

Daniel Wiederkehr

Elisabetta Malangone

Margarita Dolgitser

机构：

[1] Harvard Medical School,Glaucoma Service, Massachusetts Eye and Ear Infirmary

[2] Allergan Inc.,undefined

[3] Analytica International,undefined

来源：

Advances in Therapy | 2009年 / 26卷

关键词：

healthcare economics; ocular hypertension; open-angle glaucoma; ophthalmology;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：947 / 958

页数：11

共 50 条

[11] Efficacy and safety of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma and ocular hypertension
Berryman, Jefferson D.
Novack, Gary D.
EXPERT REVIEW OF OPHTHALMOLOGY, 2019, 14 (4-5) : 191 - 197
[12] The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) as a primary therapy in patients with open-angle glaucoma or ocular hypertension
Sall, K
SURVEY OF OPHTHALMOLOGY, 2000, 44 : S155 - S162
[13] Pulsatile ocular blood flow in primary open-angle glaucoma and ocular hypertension
Kerr, A
Nelson, P
O'brien, C
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (06) : 1106 - 1113
[14] OCULAR HYPERTENSION OR EARLY GLAUCOMA - OCULAR HYPERTENSION VS OPEN-ANGLE GLAUCOMA
CHANDLER, PA
GRANT, WM
ARCHIVES OF OPHTHALMOLOGY, 1977, 95 (04) : 585 - 586
[15] Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
Freiberg, Josefine Clement
von Spreckelsen, Alexander
Kolko, Miriam
Azuara-Blanco, Augusto
Virgili, Gianni
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
[16] ELECTROPHYSIOLOGICAL AND PSYCHOPHYSICAL FLICKER SENSITIVITY IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION
HOLOPIGIAN, K
SEIPLE, W
MAYRON, C
KOTY, R
LORENZO, M
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1990, 31 (09) : 1863 - 1868
[17] MOTION PERCEPTION IS ABNORMAL IN PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION
SILVERMAN, SE
TRICK, GL
HART, WM
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1990, 31 (04) : 722 - 729
[18] Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Hoy, Sheridan M.
DRUGS, 2018, 78 (07) : 773 - 780
[19] Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Sheridan M. Hoy
Drugs, 2018, 78 : 773 - 780
[20] Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Makoto Araie
Kazuhisa Sugiyama
Kenji Aso
Koji Kanemoto
Kalyani Kothapalli
Casey Kopczynski
Michelle Senchyna
David A. Hollander
Advances in Therapy, 2021, 38 : 1757 - 1775

← 1 2 3 4 5 →